Kala Pharmaceuticals, Inc. Stock News

ARLINGTON, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA) (“KALA” or the “Company”), today announced that it has entered into definitive agreements for the purchase of an aggregate of 10,000,000 shares of its common stock (or pre-funded warrants in lieu thereof), at a purchase price of $1.00 per share (or pre-funded warrant in lieu thereof) in a registered direct offering...

Always be cautious before investing in a penny stock. While some will turn out to be explosive winners, like Advanced Micro Devices, others turn out to be expensive duds.

Kala Bio (KALA -2.19%), a clinical-stage biopharmaceutical company focused on novel therapies for eye diseases, released its second quarter 2025 results on August 8, 2025. The headline was a net loss per share of $1.71 (GAAP).

-- Completed patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline data expected at the end of September 2025 -- -- Cash resources of $31.9 million as of June 30, 2025, expected to fund operations into 1Q 2026 --

ARLINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that members of management will present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference being held virtually on...

-- Topline results from the CHASE trial expected by end of Q3 2025 -- -- Potential for CHASE to serve as a pivotal trial in support of a Biologics License Application (BLA) submission, contingent on positive results --